MONARCH Platform by Johnson & Johnson: status and timeline

Milestones

No announced next step

Auris founded2007Complete.
MONARCH platform cleared by FDA2018Complete.
J&J acquires Auris for $3.4 billion2019Complete.
MONARCH QUEST with AI navigation and GE HealthCare integration clearedMar 2025Complete.
MONARCH QUEST 3 with AI nodule segmentation cleared by FDAAug 2026Complete.

Most important, last 3 months

FDA clears MONARCH QUEST 3 with AI-powered nodule segmentation for robotic-assisted bronchoscopyAug 2026

Current obstacles

Variable anatomyAirway structure differs per patient. Real-time registration must account for breathing and position changes.
Lesion accessEarly lesions are small and peripheral. Reaching them safely while maintaining visualization is challenging.

Physics limits

Scope stiffness vs flexibility trade-offA flexible scope reduces patient trauma but is harder to control precisely. The robotic system must compensate through software algorithms.
Image quality at depthAs the scope advances into smaller airways, the field of view shrinks and lighting becomes challenging, reducing visibility for lesion identification.

How it works

3 parts

Flexible scope

Minimally invasive lung access

Flexible bronchoscope slides down the airway, guided by robotics. Real-time tip tracking shows surgeon position relative to anatomy.

AI segmentation

Automatic nodule boundaries

QUEST 3 AI generates nodule boundaries during planning using cone-beam CT, helping surgeons target lesions precisely.

Navigation

3D Compass overlay

3D Compass helps clinicians orient the bronchoscope relative to anatomy as landmarks shift during procedures.

Spec sheet

Spec	MONARCH Platform
Real-time scope-tip tracking	Continuous 3D visualization^R (reported)

^R reported by the company

Update log

1 update

Aug 2026

Major: FDA clears MONARCH QUEST 3 with AI-powered nodule segmentation for robotic-assisted bronchoscopyPressRegulatory

About Johnson & Johnson

The team behind MONARCH Platform

Johnson & Johnson

Ottava surgical robot, Polyphonic ecosystem, MedTech division

Johnson & Johnson's MedTech division develops medical devices and surgical robotics. Ottava, FDA-approved July 2026, is the first table-integrated robotic system for soft tissue surgery, reducing OR footprint 30-50% with automated positioning.

MedTech division is 36% of JNJ revenue; $8.6B sales Q1 2026, up 7.7%.
Ottava: FDA de novo authorization July 22, 2026 for 10 general surgery procedures.
Table-integrated design saves 30-50% OR space, automated positioning, Polyphonic digital ecosystem.

jnjmedtech.com (opens jnjmedtech.com)Company profile →

Founded: 1887139 yrs
Headquarters: United States
Status: Public
Valuation: public
Works in: RoboticsSurgical & medical
Coverage: 3 programs · 3 updateslatest 1 Aug 2026checked 10 Oct
Suppliers: Intuitive Surgical (opens intuitive.com)

Spec

MONARCH Platform

Real-time scope-tip tracking

Continuous 3D visualization^R (reported)